SYNTHEKINE

Using our team's cumulative expertise and our proprietary cytokine platforms, we are developing a broad, deep pipeline of selective immunotherapies against a wide range of important targets for the treatment of cancers and autoimmune / inflammatory diseases... To address the key limitations of current cytokine therapeutics and cell therapies, we are developing potentially transformative medicines using three distinct cytokine modalities: cytokine partial agonists, orthogonal cytokine + cell therapies, and surrogate cytokine agonists... Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.

Primary location: Menlo Park United States